BioXcel Therapeutics, Inc. (BTAI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 800K 1.6M 2.4M Q3 '24: 2.3M Q4 '24: 2.3M Q1 '25: 1.9M Q2 '25: 868K Q3 '25: 752K Q4 '25: 642K Q1 '26: 680K Q2 '26: 742K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit TTM

-1.5M -1M -500K 0 500K 1M 1.5M Q3 '24: 250K Q4 '24: 122K Q1 '25: -226K Q2 '25: -1.3M Q3 '25: -212K Q4 '25: 478K Q1 '26: 247K Q2 '26: 394K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '24: -76.6M Q4 '24: -67.2M Q1 '25: -53.2M Q2 '25: -51.7M Q3 '25: -50.7M Q4 '25: -50.5M Q1 '26: -50.6M Q2 '26: -44.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income TTM

-90M -60M -30M 0 30M 60M 90M Q3 '24: -71M Q4 '24: -59.6M Q1 '25: -40.1M Q2 '25: -51M Q3 '25: -68.2M Q4 '25: -69.9M Q1 '26: -75.3M Q2 '26: -70.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue TTM

0 800K 1.6M 2.4M Q3 '24: 2M Q4 '24: 2.1M Q1 '25: 2.1M Q2 '25: 2.1M Q3 '25: 964K Q4 '25: 164K Q1 '26: 433K Q2 '26: 348K Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-90M -60M -30M 0 30M 60M 90M Q3 '24: -84.1M Q4 '24: -72M Q1 '25: -66.4M Q2 '25: -55.8M Q3 '25: -58.2M Q4 '25: -57.6M Q1 '26: -57.4M Q2 '26: -50.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow TTM

-150M -100M -50M 0 50M 100M 150M Q2 '22: -105.8M Q3 '22: -116.8M Q4 '22: -135.5M Q2 '25: -55.8M Q3 '25: -58.2M Q4 '25: -57.6M Q1 '26: -57.4M Q2 '26: -50.9M Q2 '22 Q3 '22 Q4 '22 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '24: 1.9M Q2 '24: 2.5M Q3 '24: 2.6M Q1 '25: 4.8M Q2 '25: 7.8M Q3 '25: 14.2M Q1 '26: 23.6M Q2 '26: 30.3M Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-120.00 -80.00 -40.00 0.00 40.00 80.00 120.00 Q3 '24: -115.27 Q4 '24: -25.25 Q1 '25: -12.86 Q2 '25: -12.01 Q3 '25: -9.04 Q4 '25: -5.73 Q1 '26: -4.77 Q2 '26: -2.81 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.